Angiogenic Factors and Preeclampsia

Seminars in Nephrology

Volumn 31, Issue 1, 2011, Pages 33-46

  Maynard, Sharon E ^a   Karumanchi, S Ananth ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Angiogenic factors; Endothelial dysfunction; Hypertension in pregnancy; Preeclampsia; SFlt1; VEGF

Indexed keywords

ADIPONECTIN; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ENDOGLIN; ENDOSTATIN; FMS LIKE TYROSINE KINASE 1; MONOCLONAL ANTIBODY; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; ANGIOGENESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN EDEMA; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; ECLAMPSIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FETUS DEVELOPMENT; GESTATIONAL AGE; HELLP SYNDROME; HEMOLYSIS; HUMAN; HYDATIDIFORM MOLE; HYPERCOAGULABILITY; HYPERTENSION; INTRACELLULAR SIGNALING; INTRAUTERINE GROWTH RETARDATION; KIDNEY DISEASE; LIVER INJURY; LUNG EDEMA; MATERNAL MORTALITY; NEWBORN MORTALITY; NONHUMAN; OBESITY; OLIGOHYDRAMNIOS; PATHOGENESIS; PREECLAMPSIA; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; REGULATORY MECHANISM; RISK FACTOR; SEIZURE; SIGNAL TRANSDUCTION; SOLUTIO PLACENTAE; THROMBOCYTOPENIA;

ANGIOGENESIS INHIBITORS; ANIMALS; FEMALE; FETAL GROWTH RETARDATION; HUMANS; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; SIGNAL TRANSDUCTION;

EID: 78751682439     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.10.004     Document Type: Article

References (114)

1. World health report: make every mother and child count 2005, 63. WHO, WHO, Geneva.
2. Levine R.J., Hauth J.C., Curet L.B., et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997, 337:69-76.
3. Carr D.B., Epplein M., Johnson C.O., Easterling T.R., Critchlow C.W. A sister's risk: family history as a predictor of preeclampsia. Am J Obstet Gynecol 2005, 193(Suppl 1):965-972.
4. Esplin M.S., Fausett M.B., Fraser A., et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001, 344:867-872.
5. Duckitt K., Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005, 330:565.
6. England L.J., Levine R.J., Qian C., et al. Smoking before pregnancy and risk of gestational hypertension and preeclampsia. Am J Obstet Gynecol 2002, 186:1035-1040.
7. Zhang J., Villar J., Sun W., et al. Blood pressure dynamics during pregnancy and spontaneous preterm birth. Am J Obstet Gynecol 2007, 197. 162e161-6.
8. Khan K.S., Wojdyla D., Say L., Gülmezoglu A.M., Van Look P.F. WHO analysis of causes of maternal death: a systematic review. Lancet 2006, 367:1066-1074.
9. Altman D., Carroli G., Duley L., et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002, 359:1877-1890.
10. Matsuo K., Kooshesh S., Dinc M., et al. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am J Perinatol 2007, 24:257-266.
11. Salafia C.M., Pezzullo J.C., Ghidini A., Lopez-Zeno J.A., Whittington S.S. Clinical correlations of patterns of placental pathology in preterm pre-eclampsia. Placenta 1998, 19:67-72.
12. Palmer S.K., Moore L.G., Young D., et al. Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 meters) in Colorado. Am J Obstet Gynecol 1999, 180:1161-1168.
13. Zamudio S., Wu Y., Ietta F., et al. Human placental hypoxia-inducible factor-1{alpha} expression correlates with clinical outcomes in chronic hypoxia in vivo. Am J Pathol 2007, 170:2171-2179.
14. Soleymanlou N., Jurisica I., Nevo O., et al. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 2005, 90:4299-4308.
15. Makris A., Thornton C., Thompson J., et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007, 71. 997-84.
16. Granger J.P., LaMarca B.B., Cockrell K., et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med 2006, 122:383-392.
17. Meekins J.W., Pijnenborg R., Hanssens M., McFadyen I.R., van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994, 101:669-674.
18. Zhou Y., Fisher S.J., Janatpour M., et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion. J Clin Invest 1997, 99:2139-2151.
19. Zhou Y., McMaster M., Woo K., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002, 160:1405-1423.
20. Roberts J.M., Taylor R.N., Musci T.J., et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989, 161:1200-1204.
21. Spargo B.H., McCartney C., Winemiller R. Glomerular capillary endotheliosis in toxemia of pregnancy. Arch Pathol 1959, 13:593-599.
22. Khan F., Belch J.J., MacLeod M., Mires G. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension 2005, 46:1123-1128.
23. Strevens H., Wide-Swensson D., Hansen A., et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG 2003, 110:831-836.
24. Schwartz R.B., Feske S.K., Polak J.F., et al. Preeclampsia-eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology 2000, 217:371-376.
25. Sibai B.M. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 2005, 105:402-410.
26. Ozcan C., Wong S.J., Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354:980-982.
27. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658.
28. Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004, 95:884-891.
29. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993, 90:10705-10709.
30. Thomas C.P., Andrews J.I., Raikwar N.S., et al. A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. J Clin Endocrinol Metab 2009, 94:2524-2530.
31. Heydarian M., McCaffrey T., Florea L., et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta 2009, 30:250-255.
32. Sela S., Itin A., Natanson-Yaron S., et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008, 102:1566-1574.
33. Rajakumar A., Powers R.W., Hubel C.A., et al. Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta 2009, 30:25-34.
34. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
35. Chaiworapongsa T., Romero R., Espinoza J., et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004, 190:1541-1550.
36. Robinson C.J., Johnson D.D., Chang E.Y., Armstrong D.M., Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006, 195:255-259.
37. Lu F., Longo M., Tamayo E., et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007, 196:396.e391-396.e397.
38. Gilbert J.S., Babcock S.A., Granger J.P. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007, 50:1142-1147.
39. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.
40. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355:992-1005.
41. Rana S., Karumanchi S.A., Levine R.J., et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007, 50:137-172.
42. Robinson C.J., Johnson D.D. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol 2007, 197. 174e171-5.
43. Gilbert J.S., Gilbert S.A.B., Arany M., Granger J.P. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension 2009, 53:399-403.
44. Gu Y., Lewis D.F., Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008, 93:260-266.
45. Esser S., Wolburg K., Wolburg H., et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998, 140:947-959.
46. Maharaj A.S.R., Saint-Geniez M., Maldonado A.E., D'Amore P.A. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006, 168:639-648.
47. Gerber H.P., Wu X., Yu L., et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 2007, 104:3478-3483.
48. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF Antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003, 278:12605-12608.
49. Eremina V., Sood M., Haigh J., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111:707-716.
50. Eremina V., Jefferson J.A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-1136.
51. Zhu X., Wu S., Dahut W.L., Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007, 49:186-193.
52. Luttun A., Tjwa M., Moons L., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002, 8:831-840.
53. Calesson-Welsh L. Vascular endothelial growth factors 1999, 123. Springer, Berlin, Germany. 1st ed.
54. Wolf M., Shah A., Lam C., et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005, 193:16-22.
55. Maynard S.E., Venkatesha S., Thadhani R., Karumanchi S.A. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005, 57:1R-7R.
56. Koga K., Osuga Y., Tajima T., et al. Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 2009, In press.
57. Kanter D., Lindheimer M.D., Wang E., et al. Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol 2010, 202:184.e181-184.e185.
58. Bdolah Y., Palomaki G.E., Yaron Y., et al. Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 2006, 194:239-245.
59. Levine R.J., Qian C., Maynard S.E., et al. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 2006, 194:1034-1041.
60. Jeyabalan A., Powers R.W., Durica A.R., et al. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia. Am J Hypertens 2008, 21:943-947.
61. Mehendale R., Hibbard J., Fazleabas A., Leach R. Placental angiogenesis markers sFlt-1 and PlGF: response to cigarette smoke. Am J Obstet Gynecol 2007, 197:363.e361-363.e365.
62. Suwaki N., Masuyama H., Nakatsukasa H., et al. Hypoadiponectinemia and circulating angiogenic factors in overweight patients complicated with pre-eclampsia. Am J Obstet Gynecol 2006, 195:1687-1692.
63. Crispi F., Dominguez C., Llurba E., et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006, 195:201-207.
64. Stepan H., Kramer T., Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007, 92:2831-2834.
65. Romero R., Nien J.K., Espinoza J., et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008, 21:9-23.
66. Jeyabalan A., McGonigal S., Gilmour C., Hubel C.A., Rajakumar A. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 2008, 29:555-563.
67. Cudmore M., Ahmad S., Al-Ani B., et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007, 115:1789-1797.
68. Al-Ani B., Hewett P.W., Cudmore M.J., et al. Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells. Hypertension 2010, 55:689-697.
69. Zenclussen A.C., Lim E., Knoeller S., et al. Heme oxygenases in pregnancy II: HO-2 is downregulated in human pathologic pregnancies. Am J Reprod Immunol 2003, 50:66-76.
70. Zhao H., Wong R.J., Kalish F.S., Nayak N.R., Stevenson D.K. Effect of heme oxygenase-1 deficiency on placental development. Placenta 2009, 30:861-868.
71. Zhou C.C., Zhang Y., Irani R.A., et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008, 14:855-862.
72. Zhou C.C., Irani R.A., Zhang Y., et al. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-{alpha} induction contributes to increased soluble endoglin production in preeclampsia. Circulation 2010, 121:436-444.
73. Kanasaki K., Palmsten K., Sugimoto H., et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008, 453:1117-1121.
74. Lee S.B., Wong A.P., Kanasaki K., et al. Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol 2010, 176:710-720.
75. Bolin M., Wiberg-Itzel E., Wikstrom A.-K., et al. Angiopoietin-1/angiopoietin-2 ratio for prediction of preeclampsia. Am J Hypertens 2009, 22:891-895.
76. Leinonen E., Wathen K.A., Alfthan H., et al. Maternal serum angiopoietin-1 and -2 and tie-2 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 2010, 95:126-133.
77. Hirokoshi K., Maeshima Y., Kobayashi K., et al. Elevated serum sFlt-1/Ang-2 ratio in women with preeclampsia. Nephron Clin Pract 2007, 106:c43-c50.
78. DeVader S.R., Neeley H.L., Myles T.D., Leet T.L. Evaluation of gestational weight gain guidelines for women with normal prepregnancy body mass index. Obstet Gynecol 2007, 110:745-751.
79. Mazaki-Tovi S., Romero R., Vaisbuch E., et al. Maternal serum adiponectin multimers in preeclampsia. J Perinat Med 2009, 37:349-363.
80. Ouyang Y.Q., Li S.J., Zhang Q., et al. Plasma sFlt-1-to-PlGF ratio is correlated with inflammatory but not with oxidative stress in Chinese preeclamptic women. Arch Gynecol Obstet 2009, 280:91-97.
81. Ichida K., Moriyama T., Morita H., et al. Plasma adiponectin concentrations and placental adiponectin expression in pre-eclamptic women. Gynecol Endocrinol 2007, 23:238-243.
82. Masuyama H., Segawa T., Sumida Y., et al. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG 2010, 117:314-320.
83. Nien J.K., Mazaki-Tovi S., Romero R., et al. Adiponectin in severe preeclampsia. J Perinat Med 2007, 35:503-512.
84. Wathen K.A., Ylikorkala O., Andersson S., et al. Maternal serum endostatin at gestational weeks 16-20 is elevated in subsequent pre-eclampsia but not in intrauterine growth retardation. Acta Obstet Gynecol Scand 2009, 88:593-598.
85. Conde-Agudelo A., Villar J., Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004, 104:1367-1391.
86. Grill S., Rusterholz C., Zanetti-Dallenbach R., et al. Potential markers of preeclampsia-a review. Reprod Biol Endocrinol 2009, 7:70.
87. Moore Simas T.A., Crawford S.L., Solitro M.J., et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007, 197. 244e241-8.
88. Taylor R.N., Grimwood J., Taylor R.S., et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003, 188:177-182.
89. Polliotti B.M., Fry A.G., Saller D.N., et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003, 101:1266-1274.
90. Park C.W., Park J.S., Shim S.S., et al. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 2005, 193:984-989.
91. Vatten L.J., Eskild A., Nilsen T.I., et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007, 196. 239e231-6.
92. Suzuki H., Ohkuchi A., Mastubara S., et al. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 2009, 54:1129-1135.
93. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004, 89:770-775.
94. Smith G.C.S., Crossley J.A., Aitken D.A., et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007, 109:1316-1324.
95. Kusanovic J.P., Romero R., Chaiworapongsa T., et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009, 22:1021-1038.
96. Tidwell S.C., Ho H.N., Chiu W.H., Torry R.J., Torry D.S. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001, 184:1267-1272.
97. Lynch A., Murphy J., Gibbs R., et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 2010, 117:456-462.
98. Herse F., Verlohren S., Wenzel K., et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension 2009, 53:393-398.
99. Baumann M.U., Bersinger N.A., Mohaupt M.G., et al. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008, 199:266.e261-266.e266.
100. Powers R.W., Roberts J.M., Cooper K.M., et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005, 193:185-191.
101. Levine R.J., Thadhani R., Qian C., et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005, 293:77-85.
102. Buhimschi C.S., Norwitz E.R., Funai E., et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005, 192:734-741.
103. Giguere Y., Charland M., Bujold E., et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2010, 56:361-375.
104. Levine R.J., Lindheimer M.D. First-trimester prediction of early preeclampsia: a possibility at last!. Hypertension 2009, 53:747-748.
105. Lim J.H., Kim S.Y., Park S.Y., et al. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008, 111:1403-1409.
106. Shan H.Y., Rana S., Epstein F.H., et al. Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis. Am J Kidney Dis 2008, 51:1029-1032.
107. Young B., Levine R.J., Salahuddin S., et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2009, 1-6.
108. Hladunewich M.A., Steinberg G., Karumanchi S.A., et al. Angiogenic factor abnormalities and fetal demise in a twin pregnancy. Nat Rev Nephrol 2009, 5:658-662.
109. Signore C., Mills J.L., Qian C., et al. Circulating soluble endoglin and placental abruption. Prenat Diagn 2008, 28:852-858.
110. Bergmann A., Ahmad S., Cudmore M., et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 2010, 14:1857-1867.
111. Li Z., Zhang Y., Ying Ma J., et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007, 50:686-692.
112. Karumanchi S.A., Maynard S.E., Stillman I.E., Epstein F.H., Sukhatme V.P. Preeclampsia: a renal perspective. Kidney Int 2005, 67:2101-2113.
113. Karumanchi S.A., Epstein F.H. Placental ischemia-cause or consequence of preeclampisa? Kidney Int 2007, 71:959-961.
114. Maynard S.E., Thadhani R. Pregnancy and the kidney. J Am Soc Nephrol 2009, 20:14-22.